Hormesis Shifts the No-Observed-Adverse-Effect Level (NOAEL)

Data from recent dose-response toxicological studies suggest that the no-observed-adverse-effect-level (NOAEL) may depend upon whether hormesis is present. A further examination of these data supports this hypothesis by showing that the NOAEL was greater for living units (organisms or cells) showing...

Full description

Saved in:
Bibliographic Details
Published inDose-response Vol. 19; no. 1; p. 15593258211001667
Main Authors Agathokleous, Evgenios, Saitanis, Costas, Markouizou, Athina
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.01.2021
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Drug dosages
Hormesis
Pharmacology
Toxicology
susceptibility screening
toxicological threshold
biphasic response
non-clinical risk assessment
point of departure (POD)
organism tolerance limits
Online AccessGet full text

Cover

More Information
Summary:Data from recent dose-response toxicological studies suggest that the no-observed-adverse-effect-level (NOAEL) may depend upon whether hormesis is present. A further examination of these data supports this hypothesis by showing that the NOAEL was greater for living units (organisms or cells) showing hormesis than for living units showing no hormesis. For example, some cancer tissue cells may exhibit hormetic responses to an anticancer drug while some other cancer tissue cells may not. These findings suggest that living units showing hormesis may also be less susceptible than living units not showing hormesis. However, these findings are preliminary and cannot be generalized or assumed to be a norm yet. New studies are needed to evaluate how NOAEL shifts depending on the occurrence of hormesis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1559-3258
1559-3258
DOI:10.1177/15593258211001667